English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective Glioma was the most common type of intracranial malignant tumor. Even after standard treatment, the recurrence and malignant progression of lower-grade gliomas (LGGs) were almost inevitable. The overall survival (OS) of patients with LGG varied widely, making it critical for prognostic prediction. Small G Protein Signaling Modulator 1 ( SGSM1 ) has hardly been studied in gliomas. Therefore, we aimed to investigate the prognostic role of  SGSM1  and its relationship with immune infiltration in LGGs. Methods We obtained RNA sequencing data from The Cancer Genome Atlas (TCGA) to analyze  SGSM1  expression. Functional enrichment analyses, immune infiltration analyses, immune checkpoint analyses, and clinicopathology analyses were performed. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors. And nomogram model has been developed. Kaplan–Meier survival analysis and log-rank test were used to estimate the relationship between OS and  SGSM1  expression. The survival analyses and Cox regression were validated in datasets from the Chinese Glioma Genome Atlas (CGGA). Results SGSM1  was significantly down-regulated in LGGs. Functional enrichment analyses revealed  SGSM1  was correlated with immune response. Most immune cells and immune checkpoints were negatively correlated with  SGSM1  expression. The Kaplan–Meier analyses showed that low  SGSM1  expression was associated with a poor outcome in LGG and its subtypes. The Cox regression showed  SGSM1  was an independent prognostic factor in patients with LGG (HR = 0.494, 95%CI = 0.311–0.784,  P  = 0.003). Conclusion SGSM1  was considered to be a new prognostic biomarker for patients with LGG. And our study provided a potential therapeutic target for LGG treatment.

Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas